{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-016224","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2025-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.422804+00:00","generated_at":"2026-05-27T05:35:02.943578+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TX45 Phase 1b data show 17.9% PCWP reduction in PH-HFpEF; >30% PVR cut in CpcPH subgroup","bullets":["TX45 achieved 17.9% reduction in PCWP (overall population) and >30% reduction in PVR in CpcPH patients.","Cardiac output increased 17.4%; mean pulmonary artery pressure reduced 15.9% across the total study.","No serious/severe adverse events, discontinuations, or significant hypotension; well tolerated.","APEX Phase 2 trial in PH-HFpEF is underway; topline results expected in 2026.","Data support enrichment of CpcPH patients in APEX; Part B of Phase 1b (PH-HFrEF) starts February 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-016224","json":"https://secwatch.observer/filing/0001193125-25-016224.json","markdown":"https://secwatch.observer/filing/0001193125-25-016224.md","text":"https://secwatch.observer/filing/0001193125-25-016224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312525016224/0001193125-25-016224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312525016224/d817477d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T05:35:02.943578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}